Edition:
United States

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

0.64USD
19 Oct 2018
Change (% chg)

$-0.04 (-5.15%)
Prev Close
$0.68
Open
$0.68
Day's High
$0.69
Day's Low
$0.64
Volume
101,169
Avg. Vol
180,638
52-wk High
$4.04
52-wk Low
$0.64

Latest Key Developments (Source: Significant Developments)

Advaxis Q3 Loss Per Share $0.27
Monday, 10 Sep 2018 04:30pm EDT 

Sept 10 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 THIRD QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.QTRLY REVENUE $1.1 MILLION VERSUS $3.1 MILLION.Q3 LOSS PER SHARE $0.27.  Full Article

Advaxis Provides Update On MAA Filing And ADXS-Hot Program
Tuesday, 10 Jul 2018 08:00am EDT 

July 10 (Reuters) - Advaxis Inc ::ADVAXIS PROVIDES UPDATE ON MAA FILING AND ADXS-HOT PROGRAM.ADVAXIS INC - CONTINUES TO BELIEVE THAT RESULTS FROM GOG-0265 STUDY ARE CLINICALLY MEANINGFUL.ADVAXIS - PLANS TO WITHDRAW CONDITIONAL MAA IN EUROPEAN UNION FOR AXALIMOGENE FILOLISBAC TO TREAT METASTATIC CERVICAL CANCER.ADVAXIS INC - CONTINUES TO BELIEVE AXALIMOGENE FILOLISBAC DEMONSTRATED CLINICAL ACTIVITY IN METASTATIC CERVICAL CANCER.ADVAXIS INC - HAS SUBMITTED AN IND WITH FDA TO STUDY ITS FIRST PRODUCT CANDIDATE FROM ADXS-HOT PROGRAM, ADXS-503, FOR TREATMENT OF NSCLC.ADVAXIS INC - REGULATORY ACTION IN EUROPE IS BASED ON EMA FEEDBACK FOLLOWING INITIAL REVIEW INDICATING APPLICATION WILL LIKELY NEED ADDITIONAL DATA.ADVAXIS INC - WITHDRAWAL OF MAA DOES NOT IMPACT ONGOING CLINICAL TRIALS OF AXALIMOGENE FILOLISBAC.ADVAXIS INC - EXPECTS FIRST PATIENT FOR ADXS-503, WILL BE DOSED BY END OF 2018.ADVAXIS INC - AFFIRMS PLANS TO SUBMIT A TOTAL OF FOUR INDS FOR DRUG CANDIDATES FROM ITS ADXS-HOT PROGRAM BY END OF CALENDAR YEAR 2019.ADVAXIS INC - ANTICIPATES SUBMITTING SECOND IND FROM ADXS-HOT PROGRAM WITHIN NEXT SIX MONTHS, FOR ITS DRUG ADXS-504 TO TREAT PROSTATE CANCER.  Full Article

Advaxis Reports Q1 Loss Per Share $0.49
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB).Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.ADVAXIS - FDA NOTIFIED IND FOR PHASE 1/2 COMBO STUDY OF AXALIMOGENE FILOLISBAC WITH IMFINZI FOR HPV-ASSOCIATED CANCERS WAS PLACED ON CLINICAL HOLD.CLINICAL HOLD PERTAINS TO RECENT SUBMISSION OF SAFETY REPORT TO FDA REGARDING GRADE 5 SERIOUS ADVERSE EVENT ON FEBRUARY 27.ADVAXIS - ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS CLINICAL PROGRAMS ARE UNAFFECTED AT THIS TIME.ADVAXIS - "WE ARE CONFIDENT IN SAFETY AND EFFICACY PROFILE OF AXALIMOGENE FILOLISBAC, TO DATE".  Full Article

Advaxis Prices $20.0 Mln Public Offering Of Common Stock
Thursday, 22 Feb 2018 09:15am EST 

Feb 22 (Reuters) - Advaxis Inc ::ADVAXIS PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $2.00PER SHARE.  Full Article

Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31
Wednesday, 21 Feb 2018 04:58pm EST 

Feb 21 (Reuters) - Advaxis Inc ::ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING.  Full Article

Advaxis Announces Proposed Public Offering Of Common Stock
Wednesday, 21 Feb 2018 04:05pm EST 

Feb 21 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union
Tuesday, 13 Feb 2018 08:30am EST 

Feb 13 (Reuters) - Advaxis Inc ::ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION.ADVAXIS INC - COMPANY WILL CONTINUE ASSESSING PARTNERSHIP OPPORTUNITIES FOR POTENTIAL COMMERCIALIZATION OF AXALIMOGENE FILOLISBAC IN EUROPE.ADVAXIS- DECIDED TO ALIGN, SIMPLIFY STRATEGY BY USING AXALIMOGENE FILOLISBAC EXCLUSIVELY IN ALL ONGOING AND PLANNED HPV-RELATED CANCER CLINICAL TRIALS.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 08:05am EST 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

Advaxis Q4 loss per share $1.74
Monday, 11 Sep 2017 04:01pm EDT 

Sept 11 (Reuters) - Advaxis Inc :Advaxis reports business update and third quarter 2017 results.Q4 loss per share $1.74.  Full Article

Advaxis names ‍Anthony Lombardo interim CEO
Thursday, 6 Jul 2017 04:30pm EDT 

July 6 (Reuters) - Advaxis Inc :Advaxis announces change in leadership.Advaxis inc - ‍Anthony Lombardo named interim chief executive officer​.Advaxis inc - ‍Daniel J. O'Connor, chief executive officer, announced his resignation from company​.  Full Article

BRIEF-Advaxis Announces Executive Leadership Changes

* ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER